PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

63.12 -0.34 (-0.54%)

Delayed Quote Updated: 10:21 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential ↗

July 03, 2025

PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

June 16, 2025

From The Schall Law Firm

Via Business Wire

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗

June 14, 2025

PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth...

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

June 02, 2025

From Pomerantz LLP

Via GlobeNewswire

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 28, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 28, 2025

From Pomerantz LLP

Via GlobeNewswire

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 27, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 22, 2025

From Pomerantz LLP

Via GlobeNewswire

PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗

May 22, 2025

PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 18, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 13, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 09, 2025

From Pomerantz LLP

Via GlobeNewswire

This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday ↗

May 09, 2025

Via Benzinga

Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 07, 2025

Via Benzinga

This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

May 07, 2025

Via Benzinga

PTC Therapeutics (PTCT) Q1 2025 Earnings Call ↗

May 06, 2025

Via The Motley Fool

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? ↗

May 05, 2025

PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 05, 2025

Via Benzinga

Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗

May 05, 2025

Via Benzinga

These stocks are gapping in today's session ↗

May 05, 2025

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

These stocks that are showing activity before the opening bell on Monday. ↗

May 05, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

9 Health Care Stocks With Whale Alerts In Today's Session ↗

April 22, 2025

Via Benzinga

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder ↗

March 28, 2025

PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.

Via Benzinga

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July ↗

March 20, 2025

PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.